MobilEye Global Inc (MBLY) Stock Price Today
Aura AI Summary
Key Stats
- $6.00BMarket Cap
- 7,007,849Volume
- Consumer CyclicalSector
- $15.4252W High
- $6.5652W Low
- 15 DaysTypical Hold Time
- $4.56BEnterprise Value
- -Div Yield
- -Trading Activity
Track MobilEye Global Inc (MBLY) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, MobilEye Global Inc has traded between a low of $6.56 and a high of $15.42, highlighting its annual price range. Buy and sell MobilEye Global Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About MobilEye Global Inc
Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Most Recent News
ZenaTech launches AI-powered smart safety glasses Stacklens for field technicians, with pilots in 2027.
ZenaTech introduced Stacklens™, AI-powered smart safety glasses designed for field technicians and industrial workers, integrating hands-free AI assistance, real-time video support, and thermal imaging. The glasses aim to improve efficiency by allowi...

Class action lawsuit filed over Compass-Anywhere merger alleging regulatory misrepresentation.
The Rosen Law Firm has filed a class action lawsuit on behalf of former Anywhere Real Estate shareholders who received Compass, Inc. stock in a January 2026 merger. The suit alleges that Compass and its executives misrepresented their efforts to secu...

New data supports Furoscix ReadyFlow autoinjector for outpatient edema management in heart failure and CKD.
MannKind presented new clinical data at HFSA 2026 showing that Furoscix ReadyFlow, an autoinjector delivering subcutaneous furosemide, provides diuretic effects comparable to IV administration for treating edema in heart failure and chronic kidney di...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.